Clinical Trials Browser

Phase 2 × Hereditary Sensory and Autonomic Neuropathies × Clear all

Hereditary Sensory and Autonomic Neuropathies, Endometrial Neoplasms

NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT06433219 2026-02-18

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Phase 2 Active not recruiting

63 enrolled

Gynecologic

Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms

NCT05010031 2026-01-23

A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change

Phase 2 Recruiting

40 enrolled

Neoplasm Metastasis, Hereditary Sensory and Autonomic Neuropathies

NCT03056755 2026-01-13

BYLieve

Phase 2 Completed

383 enrolled 16 charts

Breast

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT05054725 2026-01-06

Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

Phase 2 Completed

47 enrolled 17 charts

Thoracic

Bronchial Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Respiratory Tract Diseases, Respiratory Tract Neoplasms

NCT06463028 2025-12-24

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

Phase 2 Recruiting

40 enrolled

Gynecologic

Genital Diseases, Hereditary Sensory and Autonomic Neuropathies, Endometrial Neoplasms, Carcinoma, Endometrioid

NCT04564027 2025-08-29

A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer

Phase 2 Completed

54 enrolled 16 charts

Hereditary Sensory and Autonomic Neuropathies

NCT04038502 2025-08-20

COBRA

Phase 2 Recruiting

100 enrolled

Classical hematologyGenitourinary

Fanconi Anemia, Complementation Group N, Fanconi Anemia, Complementation Group D1, Hereditary Sensory and Autonomic Neuropathies, Prostatic Neoplasms

NCT03126019 2025-03-14

CITADEL-203

Phase 2 Completed

126 enrolled 15 charts

Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Hereditary Sensory and Autonomic Neuropathies

NCT04899349 2024-10-09

EPIK-B4

Phase 2 Terminated

2 enrolled 8 charts

Breast

Breast Neoplasms, Hyperglycemia, Hereditary Sensory and Autonomic Neuropathies

NCT04768296 2024-09-26

Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)

Phase 2 Completed

76 enrolled 42 charts

Thoracic

Hereditary Sensory and Autonomic Neuropathies, Small Cell Lung Carcinoma

NCT05103358 2024-06-03

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

Phase 2 Active not recruiting

120 enrolled

Tuberous Sclerosis 1, Tuberous Sclerosis 2, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT02718300 2024-05-01

A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Phase 2 Terminated

74 enrolled 40 charts

Myeloid

Myeloproliferative Disorders, Hereditary Sensory and Autonomic Neuropathies, Primary Myelofibrosis

NCT04163419 2024-03-13

Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis

Phase 2 Unknown

9 enrolled

Schwannomatosis, Neurilemmoma, Hereditary Sensory and Autonomic Neuropathies, Pain

NCT01320085 2024-01-24

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Phase 2 Completed

183 enrolled 35 charts

Dermatologic

Melanoma, Hereditary Sensory and Autonomic Neuropathies

NCT03565991 2023-09-25

Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors

Phase 2 Terminated

202 enrolled 31 charts

Hereditary Sensory and Autonomic Neuropathies

NCT03386162 2022-11-28

SAFIR-PI3K

Phase 2 Terminated

31 enrolled

Breast

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT01276379 2021-07-02

POSIBA

Phase 2 Completed

221 enrolled 17 charts

Gastrointestinal

Neoplasm Metastasis, Hereditary Sensory and Autonomic Neuropathies, Colorectal Neoplasms

NCT01942993 2020-09-30

The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma

Phase 2 Terminated

3 enrolled 2 charts

Dermatologic

Melanoma, Hereditary Sensory and Autonomic Neuropathies

NCT01640444 2019-04-11

VISNU-2

Phase 2 Completed

240 enrolled

Gastrointestinal

Neoplastic Cells, Circulating, Hereditary Sensory and Autonomic Neuropathies, Colorectal Neoplasms

NCT02644122 2018-07-11

SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes

Phase 2 Terminated

1 enrolled 6 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Hereditary Sensory and Autonomic Neuropathies

Clinical Trials

MITO END-4

9-ING-41 in Patients With Advanced Cancers

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change

BYLieve

Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer

COBRA

CITADEL-203

EPIK-B4

Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors

SAFIR-PI3K

POSIBA

The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma

VISNU-2

SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes